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Background: Paclitaxel is active in non–small-cell lung cancer
(NSCLC) and is a radiosensitizer with a dose-response relationship
that depends more on duration of exposure than peak concentration.
A continuous infusion prolongs exposure and may maximize the
drug-radiation interaction. The goal of this National Cancer Insti-
tute-sponsored phase I study was to determine the feasibility and
toxicity of a continuous infusion paclitaxel (24 hours/day, 7 days/
week, 7 weeks total) concurrent with standard radiation therapy
(RT) for locally advanced NSCLC.
Methods: Eligible patients had locally advanced (T4, N1-3, M0 or
Tany, N2-3, M0) NSCLC, performance status less than or equal to
2, and adequate hematological, hepatic, renal, and pulmonary func-
tion. RT was given to a total dose of 64.8 Gy at 1.8 Gy/day.
Paclitaxel was delivered by infusion beginning 48 hours before and
then continuously throughout the 7 weeks of RT. The paclitaxel
concentration was escalated in sequential dose cohorts ranging from
0.5 to 17 mg/m2/d, and each contained at least three patients in a
standard phase I design.
Results: Twenty-nine patients were enrolled. Significant grade 3
toxicity was observed in one patient, who experienced grade 3
pneumonitis at the 6.5-mg/m2/day dose level. This cohort was
expanded, but none of four additional patients experienced signifi-
cant toxicity. Three patients completed the 15-mg/m2/day dose level
without serious or dose-limiting toxicity. The two patients entered at
the 17-mg/m2/day dose level had grade 4 neutropenia requiring a
delay in therapy of more than 1 week. The median survival of all
patients was 12 months; however, 4 of 27 patients (15%) survived
longer than 60 months (mean 63.4 months).
Conclusion: The maximally tolerated and recommended phase II
paclitaxel dose delivered by protracted continuous infusion is 15
mg/m2/day when combined with thoracic RT. This schedule allows
for the delivery of more total paclitaxel than other published regi-
mens and may have less esophagitis than weekly paclitaxel regi-
mens. This regimen has the potential to achieve a radiosensitizing
serum concentration of paclitaxel continuously for 7 weeks without
exceeding levels associated with neutropenia or neurotoxicity. There
were four long-term survivors in this phase I study. These data
suggest that continuous paclitaxel infusion with concurrent RT is
safe and should be of interest to explore in combination with other
cytotoxic or targeted therapies.
Key Words: Paclitaxel, Radiation therapy, non-small cell lung
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(J Thorac Oncol. 2006;1: 38–45)
Thoracic radiotherapy (TRT) is a long-established treat-ment for locally advanced, non-metastatic non–small-cell
lung cancer (NSCLC). However despite delivery of acceler-
ated1 or escalated2–5 radiation approaching the maximally
tolerated dose, loco-regional and distant recurrences remain
major patterns of failure.4,6 The recognition of these problems
led to studies integrating chemotherapy with TRT.7 These
demonstrated improved cancer control and survival outcomes
for patients with NSCLC, especially when delivered concur-
rently.5,8–12
Paclitaxel (Taxol; Bristol-Myers Squibb, Princeton,
NJ) is one of the most active single agents for NSCLC, and
it is Food and Drug Administration-approved as a frontline
agent for patients with metastatic disease.13–15 Paclitaxel was
first postulated to exert anti-proliferative effects via func-
tional microtublule alteration.16–18 The resultant accumula-
tion of cells in the most radiosensitive segment of the cell
cycle, G2/M phase, offers a plausible but not, perhaps, sole
mechanism for radiosensitization seen in several tumor cell
lines, including NSCLC.19–22
Radiosensitization by paclitaxel may be limited to a
relatively narrow dose-response range of 10 to 50 nmol/L, a
concentration range markedly lower than the serum concen-
tration postinfusion over standard 1- to 24-hour infusion
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schedules.19,23,24 Preclinical studies further indicate that the
duration of exposure to paclitaxel may be more important for
its effectiveness and radiosensitization than maximal serum
concentration.25,26 NSCLC data suggest that the duration of
exposure to paclitaxel concentrations surpassing 100 nmol/L,
but not peak serum concentrations, is associated with im-
proved survival.25,26 Similarly, clinical data from a 96-hour
continuous infusion of paclitaxel in patients with metastatic
breast cancer, all of whom had already received shorter-
course taxane therapy, resulted in a response rate of 27%.27
Based on these data, we undertook separate National
Cancer Institute-Cancer Therapy Evaluation Program (CTEP)–
sponsored phase I studies of continuous-infusion paclitaxel
with concurrent radiotherapy in patients with head and neck
cancer28,29 and NSCLC. In this final report of the phase I
NSCLC trial, paclitaxel was delivered by continuous (24
hours 7 days/week during standard radiotherapy) low-dose
infusion concurrent with fixed-schedule TRT.
PATIENTS AND METHODS
The dose of paclitaxel was escalated in a standard phase
I design while a constant dose of thoracic XRT was delivered.
Our immediate objectives included assessment of practical-
ity, determination of the resultant toxicity of the regimen, and
determination of the maximal tolerated dose (MTD) of pac-
litaxel in this regimen. The ultimate aim was to identify
treatment regimens that improved survival among patients
with locally advanced NSCLC.
Patient Characteristics
Good performance status patients (Eastern Cooperative
Oncology Group grade 0-2) with biopsy-proven locally ad-
vanced, non-metastatic (T4NXM0 or TXN2-3M0) NSCLC
were eligible. Also eligible were patients with earlier-stage
tumors who were medically ineligible for surgical resection
with curative intent. Patients were required to have an forced
expiratory volume in 1 second greater than 1 liter, have no
clinically or radiographically evident pleural effusions, ex-
hibit adequate hematological parameters and hepatic func-
tion, and have serum creatinine levels less than 2 mg/dL.
Patients were not allowed to have previously received radio-
therapy or chemotherapy for NSCLC. All patients were
evaluated in a multidisciplinary clinic to determine suitability
for this trial and treatment coordination. Patients were eval-
uated and staged by physical examination, chest and upper
abdominal computed tomography with contrast, pulmonary
spirometry, and other tests as indicated clinically.
Paclitaxel
The treatment schema is shown in Figure 1. A periph-
erally inserted central catheter was used to facilitate contin-
uous-infusion drug administration. Patients were premedi-
cated with oral dexamethasone, intravenous ranitidine, and
diphenhydramine at the start of infusion. Diluted paclitaxel
preparations were administered to patient cohorts as a con-
tinuous infusion over a planned course of 1248 hours (52
days) concurrent with standard TRT. All patients in the same
cohort received the same dose of drug. The protocol design
called for paclitaxel dose escalation in patient cohorts accord-
ing to a modified Fibonacci series, as follows: 0.5, 1.0, 2.5,
4.0, 6.5, 10.5, 15.0, and 17.0 mg/m2/d. The Cancer Therapy
Evaluation Program stipulated the dose escalation and that
paclitaxel be used at a concentration in the pump of 1 mg/ml.
Freshly diluted drug was placed into a 100-ml volume cas-
sette that was changed every 48 hours. An ambulatory con-
tinuous infusion control pump with a non-polyvinyl chloride
bag and tubing was used to deliver the paclitaxel solution
through an inline filter of 0.22 microns. Dual-channel infu-
sion pumps were used with saline infusion at a higher flow
rate to keep the net infusion rates through the catheter greater
than 10 cc/hour to reduce line occlusion. Paclitaxel infusion
was started 48 hours before RT initiation and was continued
throughout the duration of RT unless held for toxicity.
Radiation Therapy Oncology Group acute radiation
toxicity and National Cancer Institute Common Toxicity
Criteria version 1.0 were used. A dose-limiting toxicity
(DLT) was defined as a grade more than or equal to 3 skin,
esophageal, or pulmonary toxicity requiring more than a
1-week treatment interruption of radiotherapy; an absolute
neutrophil count less than 1000/L; grade 4 thrombocytope-
nia; or other non-hematological grade more than or equal to
3 toxicity requiring treatment cessation for more than 1 week.
Each patient cohort contained a minimum of three patients. If
a DLT was noted in any two of three patients, the MTD was
exceeded by definition. If a DLT was noted in any one of the
three patients, an additional two patients were accrued at that
dose level. If no additional severe toxicity was noted (i.e.,
four of five patients did not have severe or life-threatening
toxicity), dose escalation proceeded to the next level. If an
additional patient experienced a DLT, then the MTD was
considered exceeded. The MTD was defined as the maximal
dose level that three of three or four of five patients com-
FIGURE 1. Treatment schema.
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pleted without DLT. Dose escalation was modified during the
trial, with CTEP-suggested cohort expansion at the 6.5-mg/
m2/day level because of observed toxicity in the simultaneous
head and neck cancer phase I trial, and the addition of a
patient with metastatic disease as CTEP-approved protocol
exemption at the 4.0- mg/m2/day dose level.
If therapy-associated severe toxicity developed during
the study, paclitaxel was held and RT continued until reso-
lution of severe toxicity to less than or equal to grade 2. The
paclitaxel infusion was then restarted a 25% reduced dose for
non-hematological toxicities but at the same dose of pacli-
taxel for hematological toxicities. Patients with longer than 2
weeks’ delay or with recurrence of severe toxicity were
removed from study. RT could continue if it was considered
unlikely that the toxicity would be worsened by continued
radiation (e.g., neutropenia or rash outside the radiation
portal). No prophylactic colony-stimulating factors were used
in this study.
Radiation Therapy
TRT delivery was the same in all cohorts, with all
patients receiving a tumor dose of 64.8 Gy. This was deliv-
ered over 7 weeks in 1.8-Gy daily fractions given for 5
days/week, using the same planning and technique as the
then-current Radiation Therapy Oncology Group protocols.30
All fields were fluoroscopically simulated, and portal films
were acquired before starting treatment and weekly during
treatment. A minimum of 4-MV megavoltage radiation was
used along with computerized treatment planning and isocen-
tric technique. Computerized dosimetry was required, and the
recommended maximal dose inhomogeneity was 5%. The
spinal cord dose was limited to 40 Gy or less, a dose chosen
arbitrarily to account for the potential radiosensitization of
critical normal tissues. Lower-risk areas encompassing ipsi-
lateral regional lymphatics without gross disease, the cepha-
lad 5 cm of subcarinal mediastinum, and electively treated
regional lymph node sites (e.g., supraclavicular nodal sites in
those patients with upper lobe extension) were treated to 50.4
Gy. Subsequently, areas with evident gross disease received
64.8 Gy.
Evaluation and Follow-Up
After completion of therapy, patients were evaluated by
physical examination at monthly intervals for the first year,
every other month for the second year, every third month for
the third year, and every sixth month thereafter. Computed
tomographic imaging was performed 3 and 12 months after
therapy and annually thereafter. Chest radiographs were per-
formed at least at 6-month intervals. Tumor response by
computed tomographic imaging was assessed in patients to
derive a preliminary estimate of efficacy. Complete response
was defined as disappearance of all clinically evident tumors
and no new disease. A partial response was defined as a
greater than 50% reduction of the sum of the products of
perpendicular tumor measurements and no new disease. Mar-
ginal response was defined as 25 to 49% reduction in the
product of perpendicular tumor measurements without new
disease. Stable disease was defined as less than a marginal
response and less than 25% increase in the product of per-
pendicular tumor measurements without the appearance of
new lesions. Progressive disease was defined as a greater than
25% increase in the product of perpendicular diameters or
new sites of disease. Overall survival was assessed using the
Kaplan-Meier method starting from the date of treatment
initiation.
RESULTS
This National Cancer Institute-CTEP–sponsored phase
I trial was performed at the University of Texas Southwestern
Medical Center at Dallas, the University of Pennsylvania
Medical Center, and the Vanderbilt Cancer Center. All pa-
tients underwent an informed consent process and voluntarily
signed institutional review board-approved informed consent
documents.
Twenty-nine patients were enrolled in this phase I trial
between 1994 and 1998. Dose escalation occurred per proto-
col. Patient characteristics are given in Tables 1 and 2.
Fourteen patients were female, 15 were male, with a median
age of 55 years (range, 39-76 years). Most patients (24 of 29)
presented with American Joint Committee on Cancer stage
IIIB disease. Three patients presented with stage IIIA disease,
one had stage IIB disease, and one had stage IV disease. A
single patient with bulky local and minimal distant stage IV
disease was enrolled after obtaining a protocol exception
from CTEP. Twenty-seven patients (93.2%) had performance
status of 0 to 1. All but one patient received the treatment as
planned. Follow-up in surviving patients ranged from 48 to
79 months (median, 58.3 months).
Toxicity Profile
Twenty-eight patients were assessable for acute treat-
ment-related toxicity. All but one patient completed the
therapeutic course. That patient developed a tracheoesopha-
geal fistula secondary to tumor progression in the first week
of treatment and was removed from study and was thus not
assessable for toxicity. There was no non-compliance or
voluntary withdrawal. No severe allergic reactions to the
continuous infusion of paclitaxel were observed, although 17
patients (58%) had a grade less than or equal to 2 reaction. A
TABLE 1. Study Design
Treatment Plan
All patients received a total dose of 64.8-Gy megavoltage radiotherapy in
1.8-Gy daily fractions 5 d/wk. Paclitaxel was delivered by continuous
infusion starting 48 hrs before RT and continuing for the duration of
RT. The paclitaxel dose was escalated in cohorts of three patients in
standard phase 1 design, starting at 0.5 mg/m2/d.
Eligibility criteria
Locally advanced (T4NXM0 or TXN2-3M0) NSCLC or earlier-stage
tumors in patients medically ineligible for surgical resection with
curative intent
ECOG performance status 0-2
FEV1 1 L
Normal leukocyte and platelet counts, creatinine levels 2 mg/dl
ECOG, Eastern Cooperative Oncology Group; FEV1, forced expiratory volume in
1s; RT, radiation therapy; NSCLC, non–small-cell lung cancer.
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single patient at the 17-mg/m2 dose level had the infusion rate
reduced 25% to 12.5 mg/m2 for 2 weeks during treatment
after excessive fatigue and mild fevers; the patient thereafter
tolerated therapy. Maximal toxicities are reported in Table 3.
Myelosuppression was the most prevalent toxicity (Table 4).
The most prevalent high-grade toxicity was grade 4 lym-
phopenia, observed in six patients including those at low dose
levels, but this was not considered clinically relevant or
dose-limiting. Significant grade 3 toxicity was observed in
one patient who experienced grade 3 pneumonitis at the
6.5-mg/m2/day dose level. This cohort was expanded, but
none of four additional patients experienced significant tox-
icity. Two patients exhibited grade 4 neutropenia at the
17-mg/m2/d dose level: one required hospitalization for fever,
and both required treatment interruption for longer than 1
week. Additionally, grade 3 esophagitis was observed in one
patient at the 17-mg/m2/d dose level. Three patients com-
pleted the preceding dose level at 15-mg/m2/d without DLT,
thus representing the MTD as defined for this study. Grade
3 radiation dermatitis was not observed in this study, and
neuropathy and alopecia were insignificant as well.
Response and Survival
Response to therapy was analyzed in 27 of the 29
patients: one patient was excluded from analysis because of
enrollment as protocol exemption, and one patient did not
complete the protocol. Of the 27 patients who completed the
protocol, 13 (48%) had a partial response. Three patients
(11%) demonstrated a marginal response. Thus, 16 of 27
evaluated patients (59%) exhibited either a partial or marginal
response. Of the 11 patients (41%) who did not show evi-
dence of tumor reduction after therapy and were available for
evaluation, three (27%) were noted to have progressive dis-
ease, whereas eight (73%) had stable disease at the first
post-RT restaging. The response rate of patients receiving 4.0
mg/m2/d paclitaxel or less was not found to be statistically
different from those receiving the higher dose levels (Fisch-
er’s exact test p  0.6). A summary of treatment response is
listed in Table 5.
Preliminary survival data in this phase I study were
assessed for the 27 patients who completed therapy per
protocol, recognizing that they received different doses of
drug. The overall median survival was 12 months, with an
average survival time of 18 months (95% confidence interval,
10.5-27.1). Of 27 patients, four (15%) were alive at last
contact, with a follow-up of greater than 60 months. Kaplan-
Meier analysis of survival is shown in Figure 2.
DISCUSSION
NSCLC remains relatively refractory to therapy, and
patients with NSCLC have a historical survival median sur-
vival of 7 to 10 months31 and a 5-year survival rate of
approximately 13% for all stages combined. Several studies
have demonstrated a radiosensitizing effect of paclitaxel on
several tumor lines,19,32 including NSCLC.20,33,34 The weekly
administration of paclitaxel concurrent with RT has become
a standard treatment for stage III NSCLC35–37 in the United
States. Paclitaxel was initially thought to exert its effects by
the disruption of microtubules and the associated accumula-
tion of tumor cells in the relatively most radiosensitive potion
of the cell cycle, G2/M. Paclitaxel was subsequently shown to
directly promote apoptosis.38–40 The pro-apoptotic function
of paclitaxel may be important for NSCLC cell lines, given
the finding that paclitaxel-RT synergy is non-p53 mutation-
dependent in NSCLC. Other studies have explored the effects
of radiation and paclitaxel on tumor angiogenesis,41 specifi-
cally in low-dose delivery.17
Mechanistically, paclitaxel cytotoxicity is concentra-
tion-dependent, with microtubule disruption at levels less
than 9 nM, whereas G2/M blockade is observed at levels
greater than 9 nM.39 At lower concentrations, paclitaxel
seems to exert an effect through disruption of mitosis,
whereas at higher levels, signal transduction-dependent apo-
ptosis may predominate.39,42 Notably, the concentrations of
paclitaxel at which maximal radiosensitization has been dem-
onstrated are markedly below peak serum levels achieved in
standard dose schedules.22,43–45 In addition, some studies
suggest that duration of exposure is more correlated with
paclitaxel cytotoxicity19,23,27,45,46 than peak serum levels.
Maximal efficacy of paclitaxel in NSCLC occurs 18 to
48 hours post-exposure, secondary to accumulation of cells at
the G2/M boundary.47,48 The serum half-life of paclitaxel is
only 4 hours, so even daily drug administration before RT
might not take full advantage of paclitaxel/RT combinations.
TABLE 2. Patient Characteristics
Characteristic No. of patients %
Patients entered 29
Assessable for response 28 96
Assessable for toxicity 29 100
Male:female 15:14
Age (yrs)
Median 55
Range 39-76
T stage
1 1 3
2 4 14
3 7 24
4 17 59
N stage
0 8 28
1 1 3
2 13 45
3 7 24
AJCC stage
II 1 3
III A 3 10
III B 24 83
IV 1 3
PS
0 19 66
1 8 28
2 2 7
AJCC, American Joint Committee on Cancer; PS, Eastern Cooperative Oncology
Group performance status
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This trial was designed to maximize the known time and
exposure-duration area under the curve effects of paclitaxel
when combined with RT. We have previously demonstrated
that serum paclitaxel concentration may be maintained for up
to 7 weeks in the 0.01- to 0.05-M (10-50 nM) range by
protracted continuous infusion.29 This strategy was thought to
be feasible and potentially translatable to community prac-
tice, just as protracted venous infusion of 5-fluorouracil is
now standard in therapy for several gastrointestinal malig-
nancies.
The DLT in this study was found to be grade 4
neutropenia, which occurred in two patients at the 17-mg/
m2/d cohort. Thus we identified the recommended phase II
dose for paclitaxel in this regimen as 15 mg/m2/d. This
finding is consistent with other clinical and pharmacokinetic
studies demonstrating that prolonged exposure to paclitaxel
in doses greater than 50 nmol/L is associated with neutrope-
nia. As in our previous series of patients with head and neck
cancer receiving continuous-infusion paclitaxel with XRT,
the results of the present study suggest the possibility of
achieving paclitaxel levels sufficient for tumor radiosensiti-
zation but below thresholds for paclitaxel-induced neutrope-
nia, alopecia, or neuropathy. The non-hematological toxicity
findings observed in this study are similar to those observed
TABLE 3. Summary of Maximal Toxicities
No. of patients reporting given toxicity of a given grade
Toxicity 0 1 2 3 4 5
Hematological
Anemia 14 11 2 1 1 0
Leukopenia 24 1 3 0 1 0
Lymphopenia 19 0 0 2 8 0
Neutropenia 26 1 0 0 2 0
Thrombocytopenia 28 1 0 0 0 0
Mucocutaneous
Esophagitis 20 6 2 1 0 0
Skin 10 13 6 0 0 0
Gastrointestinal
Odynophagia 6 16 5 2 0 0
Dysphagia 16 12 1 0 0 0
Nausea 22 6 1 0 0 0
Diarrhea 25 4 0 0 0 0
Constipation 28 1 0 0 0 0
Vomiting 24 3 2 0 0 0
Edema 27 1 1 0 0 0
Transaminitis 29 0 0 0 0 0
Neurology 14 12 2 1 0 0
Weight loss 25 3 0 1 0 0
Allergic infusion reaction 12 11 6 0 0 0
Musculoskeletal 18 9 2 0 0 0
TABLE 4. Summary of Hematological Toxicity by Dose Level a
Maximal toxicity score by patients at dose level
Dose level
(mg/m2/d)
No. of
Patients Anemia Leukopenia Lymphopenia Thrombocytopenia Neutropenia
0.5 3 1,1,2 0,0,2 0,3,3 0,0,0 0,0,0
1 4 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,0 0,0,0,0
2.5 4 0,0,1,1 0,0,0,2 0,0,3,4 0,0,0,0 0,0,0,0
4* 4 0,1,1,2 0,0,0,0 0,4,4,4 0,0,0,2 0,0,0,0
6.5 6 0,0,0,1,1,4 0,0,0,0,0,2 0,0,0,0,3,4 0,0,0,0,0,1 0,0,0,0,0,1
10.5 3 0,0,1 0,0,1 0,0,4 0,0,0 0,0,0
15 3 0,00, 0,00, 0,0,0 0,00, 0,0,0
17 2 1,3 0,4 0,0 0,0 4,4
a Patient enrolled on protocol exemption.
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with RT alone and may be lower than those seen with other
schedules of concurrent bolus taxane-radiotherapy, such as
weekly paclitaxel with or without carboplatin.37,49,50 The
modest rate of grade 3 esophagitis in this study is particularly
notable. The use of oral and intravenous-conjugate (e.g.,
pegylated, conjugated, structurally modified, or liposomal
taxanes) may also achieve similar pharmacokinetic effects
with more convenient delivery and, possibly, improved ther-
apeutic index.51,52
Phase I studies are not designed with survival as a
primary end point, as patient inclusion may be more diverse,
and patients receive different doses of drug. Nonetheless, the
median survival in this series was 12 months, with four
patients who were presumably cured alive at 5 years. Com-
paratively, phase I and II investigation of weekly paclitax-
el/RT resulted in 20-month median and 39% projected 3-year
survival, with the single-agent phase I results similar to our
series.14 In a subsequent phase II trial of RT/paclitaxel/
carboplatin, Choy et al. 53 reported an increased median
survival of 33 months. Similar response rates of these phase
I trials and the notable low-toxicity of the low-dose contin-
uous infusion technique are appealing features of this regi-
men. Although several other series21,54–56 have assessed the
role of paclitaxel in radiosensitization, the results of this trial
encourage continued investigation of low-dose continuous-
infusion taxane chemoradiation for patients with NSCLC,
possibly in combination with one more additional anti-neo-
plastic drugs in an effort to maximize efficacy, a method
being investigated in several current trials.57–59 Specifically,
the anti-angiogenic properties of paclitaxel may provide an
impetus for combination with other targeted therapies in
addition to cytotoxic agents.17,41,58
In summary, this study demonstrates the feasibility of
continuous-infusion paclitaxel with concurrent TRT for pa-
tients with locally advanced NSCLC. The MTD and recom-
mended phase II dose of paclitaxel is 15 mg/m2/day, with
higher doses resulting in hematological toxicity that was
manageable but dose-limiting by definition. Non-hematolog-
ical toxicities, including esophagitis, were remarkably mod-
est. This dose schedule of paclitaxel allows a cumulative
paclitaxel dose during RT that is greater than that delivered
with standard once-a-week or every-three-week paclitaxel
while continuously maintaining serum concentrations for up
to 7 weeks at levels previously shown to be associated with
radiosensitization. These findings, along with the recognition
that prolonged infusion of low-dose paclitaxel may have
direct therapeutic effects, suggest that TRT in combination
with continuous-infusion paclitaxel and other cytotoxic or
targeted agents is feasible and potentially promising to im-
prove the local and systemic control of locally advanced
NSCLC.
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